Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory Disease

NCT00831467 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Hormonal Refractory Prostate Cancer

Interventions

BIOLOGICAL: CV9103

Sponsor

CureVac